Vaccine composition against malaria
AssigneeSmithKline Beecham Biologicals s.a.
InventorJoseph Cohen
Life of this patent
Estimating the term…
Abstract
This invention relates to a vaccine composition useful in the prevention or treatment of malaria comprises a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response.
Claims8
A vaccine composition for use in the prevention or treatment of malaria, comprising a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response.
A vaccine composition according to any one of the preceding claims, wherein the adjuvant comprises an oil-in-water emulsion.
A vaccine composition according to any one of the preceding claims, wherein the malaria antigens are selected from the group consisting of:
- a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more tandem repeats of the immunodominant region, and the surface antigen from Hepatitis B virus (HBsAg);
- the TRAP of a cloned isolate of P. falciparum from Thailand known as T/9/96, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
- the 16kD protein described in International Patent Application No. WO 91/18922, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
- the apical membrane antigen-1 (AMA-1) of P. falciparum or P. vivax, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
- the circumsporozoite protein (csp) of P. falciparum or P. vivax, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
- the MSP-1 of P. falciparum or P. vivax (U.S. Pat. No. 4,837,016), and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
- other exoerythrocytic stage proteins and immunogenic derivatives including fragments thereof;
- and
- optionally, blood stage proteins and immunogenic derivatives including fragments thereof.
A vaccine composition according to any one of the preceding claims, for use in therapy.
Dependencies are inferred from the claim text.